American Brachytherapy Society recommendations for reporting morbidity after prostate brachytherapy (Q30850873)

27 June 2017

1 reference

title

American Brachytherapy Society recommendations for reporting morbidity after prostate brachytherapy (English)

1 reference

27 June 2017

1 reference

Subir Nag

1

1 reference

27 June 2017

Rodney J Ellis

2

1 reference

27 June 2017

Gregory S Merrick

3

1 reference

27 June 2017

Robert Bahnson

4

1 reference

27 June 2017

Kent Wallner

5

1 reference

27 June 2017

Richard Stock

6

1 reference

27 June 2017

American Brachytherapy Society

7

1 reference

27 June 2017

language of work or name

English

0 references

publication date

1 October 2002

1 reference

International Journal of Radiation Oncology Biology Physics

27 June 2017

published in

1 reference

27 June 2017

volume

54

1 reference

27 June 2017

issue

2

1 reference

27 June 2017

page(s)

462-470

1 reference

Complications after prostate brachytherapy in the Medicare population

27 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902937-1

7 January 2021

Erectile dysfunction following minimally invasive treatments for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902937-1

7 January 2021

103Pd brachytherapy and external beam irradiation for clinically localized, high-risk prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902937-1

7 January 2021

Rectal complications associated with transperineal interstitial brachytherapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902937-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902937-1

7 January 2021

Quality-of-life comparison of radical prostatectomy and interstitial brachytherapy in the treatment of clinically localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902937-1

7 January 2021

Rectal dosimetric analysis following prostate brachytherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902937-1

7 January 2021

Rectal function following prostate brachytherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902937-1

7 January 2021

Erectile function after permanent prostate brachytherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902937-1

7 January 2021

Short-term sexual function after prostate brachytherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902937-1

7 January 2021

Potency after permanent prostate brachytherapy for localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902937-1

7 January 2021

Interstitial iodine-125 radiation without adjuvant therapy in the treatment of clinically localized prostate carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902937-1

7 January 2021

Outpatient ultrasound-guided palladium 103 brachytherapy for localized adenocarcinoma of the prostate: a preliminary report of 434 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902937-1

7 January 2021

Defining the risk of developing grade 2 proctitis following 125I prostate brachytherapy using a rectal dose-volume histogram analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902937-1

7 January 2021

Penile erectile function after permanent radioactive seed implantation for treatment of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902937-1

7 January 2021

Sexual potency following interactive ultrasound-guided brachytherapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902937-1

7 January 2021

Tumor control and morbidity following transperineal iodine 125 implantation for stage T1/T2 prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902937-1

7 January 2021

High dose combination radiotherapy for the treatment of localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902937-1

7 January 2021

Five-year biochemical outcome and toxicity with transperineal CT-planned permanent I-125 prostate implantation for patients with localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902937-1

7 January 2021

Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early-stage prostatic cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902937-1

7 January 2021

Relationship between the transition zone index of the prostate gland and urinary morbidity after brachytherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902937-1

7 January 2021

The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902937-1

7 January 2021

Sex inventories: can questionnaires replace erectile dysfunction testing?

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902937-1

7 January 2021

The UCLA Prostate Cancer Index: development, reliability, and validity of a health-related quality of life measure

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902937-1

7 January 2021

The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902937-1

7 January 2021

American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902937-1

7 January 2021

The American Brachytherapy Society recommendations for permanent prostate brachytherapy postimplant dosimetric analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902937-1

7 January 2021

The American Brachytherapy Society recommendations for brachytherapy of soft tissue sarcomas

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902937-1

7 January 2021

The MOS short-form general health survey. Reliability and validity in a patient population

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902937-1

7 January 2021

The Sickness Impact Profile: Development and Final Revision of a Health Status Measure

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902937-1

7 January 2021

The Functional Assessment of Cancer Therapy scale: development and validation of the general measure

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902937-1

7 January 2021

Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902937-1

7 January 2021

Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902937-1

7 January 2021

Measurement of quality of life in localized prostatic cancer patients treated with radiotherapy. Development of a prostate cancer-specific module supplementing the EORTC QLQ-C30.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902937-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902937-1

7 January 2021

Acute urinary morbidity following I-125 interstitial implantation of the prostate gland

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902937-1

7 January 2021

Urinary morbidity following ultrasound-guided transperineal prostate seed implantation.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902937-1

7 January 2021

Temporal resolution of urinary morbidity following prostate brachytherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902937-1

7 January 2021

Identification of patients at increased risk for prolonged urinary retention following radioactive seed implantation of the prostate.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902937-1

7 January 2021

Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC)

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902937-1

7 January 2021

Long-term treatment sequelae following external beam irradiation for adenocarcinoma of the prostate: analysis of RTOG studies 7506 and 7706.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902937-1

7 January 2021

Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902937-1

7 January 2021

Elucidating the etiology of erectile dysfunction after definitive therapy for prostatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902937-1

7 January 2021

Brachytherapy radiation doses to the neurovascular bundles

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902937-1

7 January 2021

A comparison of radiation dose to the neurovascular bundles in men with and without prostate brachytherapy-induced erectile dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902937-1

7 January 2021

Dose of radiation received by the bulb of the penis correlates with risk of impotence after three-dimensional conformal radiotherapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902937-1

7 January 2021

A comparison of radiation dose to the bulb of the penis in men with and without prostate brachytherapy-induced erectile dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902937-1

7 January 2021

Efficacy of sildenafil citrate in prostate brachytherapy patients with erectile dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902937-1

7 January 2021

Clinical course of rectal bleeding following I-125 prostate brachytherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902937-1

7 January 2021

CAncer Rehabilitation Evaluation System--short form (CARES-SF). A cancer specific rehabilitation and quality of life instrument

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902937-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902937-1

7 January 2021

Accuracy of recall in health-related quality-of-life assessment among men treated for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902937-1

7 January 2021

Sexual (dys)function after radiotherapy for prostate cancer: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2902937-1

7 January 2021

10.1016/S0360-3016(02)02937-1

Identifiers

DOI

1 reference

27 June 2017

1 reference